Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

Cambridge, UK, 6 November 2018 — Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, is pleased to be announced as joint-winner of the “Biotech Company of the Year” award at the Cambridge Independent Science & Technology Awards 2018.

Crescendo was recognised for its successful year - the Company closed a Series B financing round of $70m, reached its first two major milestones in its multi-programme collaboration with Takeda ahead of time, and signed a licensing agreement with Zai Lab. In addition to this, Crescendo has continued to build a truly world class leadership team by hiring top-tier management and non-executive directors.

Dr Peter Pack, CEO of Crescendo Biologics commented:
“We are proud to have been recognised by the industry at this year’s Cambridge Independent Awards. It’s a testament to the whole team for all their hard work and in enabling our transition from a transgenic platform provider to a developer of multi-functional Humabody therapeutics. I’d also like to congratulate the team at F-star, who were deserved joint-winners of the award.”

The Cambridge Independent Science and Technology Awards were held on 1 November at the Hilton Cambridge City Centre Hotel, and celebrated the full range of science and technology companies in the region and their achievements over the previous 12 months.

Other finalists for the “Biotech Company of the Year” award included Cambridge Epigenetix, Microbiotica, Avacta and Evonetix.

-Ends-
For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO
+ 44 (0)1223 497140
info@crescendobiologics.com

For Media:
Instinctif Partners for Crescendo Biologics
Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.